Trials / Not Yet Recruiting
Not Yet RecruitingNCT05479487
Fluzoparib and Apatinib Versus Fluzoparib in Relapsed Ovarian Carcinoma Maintenance Treatment
Fluzoparib Combined With Apatinib Versus Fluzoparib for Maintenance Treatment in Platinum-Sensitive Relapsed Ovarian Carcinoma: A Randomized, Open Label, Controlled, Multicenter Trial
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 132 (estimated)
- Sponsor
- Xiaohua Wu MD · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is a Phase II randomized, open label, controlled, multicenter study to access the effects and tolerability of fluzoparib combined with apatinib versus fluzoparib monotherapy for maintenance treatment in platinum-sensitive relapsed ovarian carcinoma (including patients previous treated with a PARP inhibitor).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fluzoparib+Apatinib | Fluzoparib 100mg bid+ Apatinib 375mg qd |
| DRUG | Fluzoparib Monotherapy | Fluzoparib 150mg bid |
Timeline
- Start date
- 2022-08-01
- Primary completion
- 2023-11-01
- Completion
- 2026-09-01
- First posted
- 2022-07-29
- Last updated
- 2022-07-29
Source: ClinicalTrials.gov record NCT05479487. Inclusion in this directory is not an endorsement.